238 related articles for article (PubMed ID: 27367716)
1. Development of Neutralization Assay Using an eGFP Chikungunya Virus.
Deng CL; Liu SQ; Zhou DG; Xu LL; Li XD; Zhang PT; Li PH; Ye HQ; Wei HP; Yuan ZM; Qin CF; Zhang B
Viruses; 2016 Jun; 8(7):. PubMed ID: 27367716
[TBL] [Abstract][Full Text] [Related]
2. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate.
Chung WC; Hwang KY; Kang SJ; Kim JO; Song MJ
J Microbiol; 2020 Jan; 58(1):46-53. PubMed ID: 31768937
[TBL] [Abstract][Full Text] [Related]
3. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
4. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout.
Gläsker S; Lulla A; Lulla V; Couderc T; Drexler JF; Liljeström P; Lecuit M; Drosten C; Merits A; Kümmerer BM
Virol J; 2013 Jul; 10():235. PubMed ID: 23855906
[TBL] [Abstract][Full Text] [Related]
5. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
Chua CL; Sam IC; Merits A; Chan YF
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
[TBL] [Abstract][Full Text] [Related]
6. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
7. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
[TBL] [Abstract][Full Text] [Related]
8. Development of a rapid antiviral screening assay based on eGFP reporter virus of Mayaro virus.
Li X; Zhang H; Zhang Y; Li J; Wang Z; Deng C; Jardim ACG; Terzian ACB; Nogueira ML; Zhang B
Antiviral Res; 2019 Aug; 168():82-90. PubMed ID: 31150677
[TBL] [Abstract][Full Text] [Related]
9. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
10. A neutralization assay for chikungunya virus infections in a multiplex format.
Weber C; König R; Niedrig M; Emmerich P; Schnierle BS
J Virol Methods; 2014 Jun; 201():7-12. PubMed ID: 24552952
[TBL] [Abstract][Full Text] [Related]
11. Neutralization Assay for Chikungunya Virus Infection: Plaque Reduction Neutralization Test.
Azami NA; Moi ML; Takasaki T
Methods Mol Biol; 2016; 1426():273-82. PubMed ID: 27233280
[TBL] [Abstract][Full Text] [Related]
12. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF
EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus.
Fumagalli MJ; de Souza WM; Espósito DLA; Silva A; Romeiro MF; Martinez EZ; da Fonseca BAL; Figueiredo LTM
Virol J; 2018 Jul; 15(1):112. PubMed ID: 30041676
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Methods for CHIKV Based on Serological Tools.
Gaibani P; Landini MP; Sambri V
Methods Mol Biol; 2016; 1426():63-73. PubMed ID: 27233261
[TBL] [Abstract][Full Text] [Related]
15. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
[TBL] [Abstract][Full Text] [Related]
16. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
18. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines.
Yoon IK; Alera MT; Lago CB; Tac-An IA; Villa D; Fernandez S; Thaisomboonsuk B; Klungthong C; Levy JW; Velasco JM; Roque VG; Salje H; Macareo LR; Hermann LL; Nisalak A; Srikiatkhachorn A
PLoS Negl Trop Dis; 2015 May; 9(5):e0003764. PubMed ID: 25951202
[TBL] [Abstract][Full Text] [Related]
19. Preparation and application of chikungunya pseudovirus containing double reporter genes.
Su C; Ding K; Xu J; Wu J; Liu J; Shen J; Zhou H; Liu H
Sci Rep; 2022 Jun; 12(1):9844. PubMed ID: 35701460
[TBL] [Abstract][Full Text] [Related]
20. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]